Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​​Now in effect: Updated preferred products for select oncology and oncology adjunct therapies​

April 5, 2022

As of April 1, 2022, Independence added new preferred products for pegfilgrastim and rituximab.

Reference products                                 Preferred products


Bevacizumab (marketed as Avastin
®)*
  • Mvasi™ (bevacizumab-awwb)
  • Zirabev® (bevacizumab-bvzr)


Pegfilgrastim (marketed as Neulasta
®)
  • Fulphila® (pegfilgrastim-jmdb)
  • Neulasta® (pegfilgrastim)
  • Ziextenzo® (pegfilgrastim-bmez) NEW!


Rituximab (marketed as Rituxan
®)
  • Riabni(rituximab-arrx) NEW!
  • Ruxience (rituximab-pvvr)


Trastuzumab (marketed as Herceptin
®)
  • Kanjinti™ (trastuzumab-anns)
  • Trazimera™ (trastuzumab-qyyp)

*Bevacizumab will continue to be covered for ophthalmologic indications, without precertification approval, for all branded products (e.g., Avastin, Mvasi, Zirabev).

Rituximab preferred products apply to all oncology and non-oncology indications.

 

To learn more about these changes and how they affect your patients, please read our announcement article.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.